Evidence suggests that bone marrow (BM) cells may give rise to a significant proportion of smooth muscle cells (SMCs) that contribute to intimal hyperplasia after vascular injury; however, the molecular pathways involved and the timeline of these events remain poorly characterized. We hypothesized that the stem cell factor (SCF)/c-Kit tyrosine kinase signaling pathway is critical to neointimal formation by BM-derived progenitors. Wire-induced femoral artery injury in mice reconstituted with wild-type BM cells expressing yellow fluorescent protein was performed, which revealed that 66Ϯ12% of the SMCs (␣-smooth muscle actin-positive [␣SMA ϩ ] cells) in the neointima were from BM. To characterize the role of the SCF/c-Kit pathway, we used c-Kit deficient W/W v and SCF-deficient Steel-Dickie mice. Strikingly, vascular injury in these mice resulted in almost a complete inhibition of neointimal formation, whereas wild-type BM reconstitution of c-Kit mutant mice led to neointimal formation in a similar fashion as wild-type animals, as did chronic administration of SCF in matrix metalloproteinase-9 -deficient mice, a model of soluble SCF deficiency. Pharmacological antagonism of the SCF/c-Kit pathway with imatinib mesylate (Gleevec) or ACK2 (c-Kit antibody) also resulted in a marked reduction in intimal hyperplasia. Vascular injury resulted in the local upregulation of SCF expression. c-Kit ϩ progenitor cells (PCs) homed to the injured vascular wall and differentiated into ␣SMA ϩ cells. Vascular injury also caused an increase in circulating SCF levels which promoted CD34 ϩ PC mobilization, a response that was blunted in mutant and imatinib mesylate-treated mice. In vitro, SCF promoted adhesion of BM PCs to fibronectin. Additionally, anti-SCF antibodies inhibited adhesion of BM PCs to activated SMCs and diminished SMC differentiation. These data indicate that SCF/c-Kit signaling plays a pivotal role in the development of neointima by BM-derived PCs and that the inhibition of this pathway may serve as a novel therapeutic target to limit aberrant vascular remodeling. (Circ Res. 2006;99:617-625.) Key Words: vascular remodeling Ⅲ genetic mice models Ⅲ vascular biology Ⅲ vascular smooth muscle Original
T he majority of hematopoietic stem cells (HSCs) and various progenitors, including endothelial progenitor cells (EPCs), reside within the osteoblastic zone of the bone marrow (BM), the so-called stem cell niche. Tissue injury releases chemical cues that induce mobilization of cells within the niche into the peripheral blood. Along with inflammatory cells, stem cells and progenitors released from the niche follow chemotactic signals to the injured tissue. Myocardial infarction (MI) or vascular injury elicit BM cell mobilization and localized inflammatory responses, required for cardiovascular repair and remodeling. [1] [2] [3] In addition to innate immune cell participation in repair, mobilized vascular endothelial and smooth muscle progenitors participate in angiogenesis and vascular repair. 1, 4 Other regenerative roles of BM-derived cells in the heart remain controversial and have not been clearly defined, but include cardiogenic differentiation, [5] [6] [7] [8] cardiac cell rescue by myelomonocytic cell fusion, 7 or the release of anti-apoptotic paracrine factors. 9 Regardless of the mechanism, induced mobilization or intracardiac injection of BM cells improves cardiac function following MI in animal models, 6, 10 which has stimulated numerous clinical trials testing the ability of BM cells either directly infused into hearts or mobilized into the periphery to improve cardiac function following MI. 11, 12 However, not all BM responses to cardiovascular injury are regenerative in nature, with recent studies demonstrating that mobilized BM cells can be a source of pathogenic vascular remodeling. Neointimal formation, with resultant vascular remodeling, is a unifying pathological event, complicating chronic atherosclerosis, restenosis, and transplant arteriopathy, and remains the major limiting factor for the long-term efficacy of vascular interventions, such as angioplasty 13 and coronary artery bypass graft surgery. 14 Although the process of neointimal formation following vascular injury was formerly ascribed solely to a local smooth muscle proliferative response, it has been demonstrated to be regulated significantly by transplantable BM-derived cells. 1, 8, [15] [16] [17] Yet, the fundamental mechanism of neointimal hyperplasia by mobilized BM cells is unknown. Thus, the identification of the molecular and cellular mechanisms underlying regenerative and pathogenic cardiovascular remodeling by mobilized BM cells is critical so that new therapeutic approaches can be used to augment the regenerative potential of BM cells while preventing restenosis.
Stem cell factor (SCF) (also known as Steel factor) is expressed as a soluble or membrane-bound form and promotes survival, 18 proliferation, 19 mobilization, 20 and adhesion 21 of hematopoietic stem cells and progenitors through dimerization of its cognate receptor, the tyrosine kinase c-Kit. 22 Granulocyte colony stimulating factor (G-CSF), stromal cell-derived factor 1 (SDF-1), or vascular endothelial growth factor (VEGF) mobilizes c-Kit ϩ progenitors and stem cells by inducing matrix metalloproteinase-9 (MMP-9) expression, which then cleaves membrane bound SCF (mSCF), activating c-Kit-induced proliferation and mobilization. 23, 24 Thus, the release of mSCF by MMP-9 following vascular injury, and the resulting c-Kit tyrosine kinase signaling, may play a mechanistic role in orchestrating the contribution of stem cell-derived vascular progenitors to vascular disease. We used both mutant and BM-reconstituted mice to provide definitive evidence that the SCF/c-Kit signaling pathway is critical to pathological neointimal formation following vascular injury.
Materials and Methods
An expanded Materials and Methods section is available in the online data supplement at http://circres.ahajournals.org.
Animals Studies
Wild-type 129S6 mice, MMP-9 Ϫ/Ϫ , W/W v (WBB6F1 hybrid strain), colony control WBB6F1 (ϩ/ϩ), Sl/Sl d (Steel-Dickie; WCB6F1hybrid strain), and colony control WCB6F1 (ϩ/ϩ) mice were used for the vascular injury studies. W/W v mice have a relative deficiency of c-Kit kinase activity although the affected cells express normal to elevated levels of c-Kit receptor and Steel-Dickie mice have a complete deficiency of mSCF and reduced serum levels of soluble SCF (sSCF).
Results

BM Cells Contribute to Neointimal Formation
Following vascular injury, vascular smooth muscle cells (VSMCs) underwent extensive apoptosis (Figure I in the online data supplement), and vessels were completely denuded of endothelial cells. A significant increase in the number of VSMCs, or neointimal formation, occurred over a 4-week period ( Figure 1A and supplemental Figure II and II1). In mice reconstituted with wild-type BM cells expressing yellow fluorescent protein (eYFP) (BMT Yfp3 Wild mice), 66Ϯ12% of the VSMCs (␣-smooth muscle actin-positive [␣SMA ϩ ] cells) in the neointima were eYFP ϩ ␣SMA ϩ ( Figure   Figure 1 . Bone marrow derived cells contribute to pathological vascular remodeling after acute vessel injury. A, Hematoxylin/eosin staining was shown in uninjured femoral arteries (D0) and femoral arteries 1, 7, 14, and 28 days after vascular injury. Arrows indicate the internal and external elastic laminae. B, Immunofluorescence double staining of the injured arteries to detect eYFP and ␣SMA in wild-type mice (BMT Yfp3Wild ) 28 days after injury. C, Immunofluorescence using anti-␣SMA (red) and anti-CD45 (green) antibodies at day 5 in nontransplanted animals. D, Immunofluorescence using eYFP (green) and anti-CD45 (red) antibody. E, Immunofluorescence analysis of femoral arteries 0 hour, 12 hour, 1 day, and 4 days after injury: SCF (green) and nuclei (red). Double immunofluorescence using anti-vimentin (green) and anti-SCF (red) antibodies with nuclei in blue (far right). F, Platelet-enriched plasma was separated from healthy human donors. After incubation with recombinant SCF, PDGF concentrations following platelet aggregation were assayed (nϭ4). *PϽ0.01, **PϽ0.001, compared with the controls. G, Western blotting shows the expression of SCF in SMCs in response to PDGF and at different time points after PDGF (10 ng/mL) stimulation. H, Immunofluorescence staining shows c-Kit ϩ cells homing to the injured vessel wall and differentiating into ␣SMAϩ cells 9 days after vascular injury. L indicates lumen.
1B), confirming earlier reports that a significant portion of the neointima is formed by BM-derived cells. 1 In addition to ␣SMA expression, the BM-derived ␣SMA ϩ cells express calponin, and caldesmon, but not for myelomonocytic markers. 25 Local vascular injury has a positive impact on progenitor cell (PC) mobilization from the BM. CD45, a pan leukocyte marker, was used to estimate the contribution of inflammatory cells to the neointima. Many CD45 ϩ BMderived cells were present in the early phase after vascular injury ( Figure 1C ). However, as cells differentiated into ␣SMA ϩ cells, few CD45 ϩ cells could be identified ( Figure  1D ) suggesting that ␣SMA ϩ progenitors were CD45 Ϫ/low or that ␣SMA ϩ progenitors were CD45 ϩ but lost CD45 expression during differentiation.
Vascular Injury Activates SCF Expression
Vascular injury resulted in the local upregulation of SCF in the adventitia and remaining VSMCs ( Figure 1E and supplemental Figure III ). Within the adventitia, most of the SCF ϩ cells were found to be vimentin ϩ (likely fibroblasts) and some of them were CD45 ϩ (likely inflammatory cells; supplemental Figure IV ), but none were CD31 ϩ (an endothelial cell marker). In vitro, preincubation with SCF enhanced plateletderived growth factor (PDGF) secretion by platelets on activation in a dose-dependent manner ( Figure 1F ). PDGF is a known stimulator of VSMC migration and promoter of neointimal proliferation. 26 -28 In turn, PDGF upregulated SCF expression by VSMCs ( Figure 1G ), suggesting the creation of a positive feedback signaling loop between SCF and PDGF. Thus, the local platelet response shortly after vascular injury may serve to secrete PDGF followed by upregulation of SCF expression, which may trigger the ensuing systemic response to injury, setting the stage for vascular remodeling. Consistent with this hypothesis, c-Kit ϩ PCs homed to the injured vascular wall and differentiated into ␣SMA ϩ cells ( Figure  1H ).
SCF and c-Kit Mutations in Mice Attenuate Neointimal Hyperplasia
To determine whether SCF/c-Kit signaling was an essential for pathological vascular remodeling in vivo, we made use of naturally occurring mutant strains of c-Kit and SCF, the W/W v and Sl/Sl d strains, respectively. W/W v mice demonstrate 15% of wild-type c-Kit activity a severe reduction in hematopoi-etic stem cells. Sl/Sl d mice express low levels of SCF and are deficient in membrane bound SCF (mSCF). Both W/W v and Sl/Sl d mice are anemic; however, the platelet and white blood cell counts are not significantly reduced. W/W v and Sl/Sl d and littermate control mice underwent femoral artery wire injury. Strikingly, in W/W v and Sl/Sl d mice, neointimal formation was significantly less than that occurring in littermate control mice (Figure 2A and 2B). To further test a causal role of SCF/c-Kit signaling in neointimal formation, we performed vascular injury following wild-type BM transplantation into W/W v mice. These transplanted mice, having BM PCs with functioning c-Kit receptor tyrosine kinase, demonstrated marked intimal hyperplasia 28 days after wire injury, similar to wild-type mice. Thus, c-Kit appears to be absolutely required for postinjury vascular remodeling. Attempting to restore normal levels of SCF to Sl/Sl d mice, we administered SCF (100 ng/kg per day) subcutaneously to these mice. Despite inducing extreme increases in plasma sSCF levels (from 0.52 ng/mL at baseline up to 10749, 4432 and 3329 ng/mL, respectively, at 6, 12, and 24 hours after injection), sSCF supplementation did not result in a significant increase in neointimal thickness (Figure 2A ; Sl/Sl d ϩSCF). Thus, SCF, namely mSCF, appears to also be required for pathological vascular remodeling to occur. sSCF cannot replace the role of mSCF in promoting neointimal formation.
Vascular Injury Increases Blood SCF Levels
Vascular injury not only upregulated local SCF expression but also caused an increase in circulating SCF levels. In wild-type mice, sSCF levels peaked on day 3 after injury and gradually returned to baseline levels ( Figure 3A ). In W/W V mice, sSCF tended to increase after injury, but baseline sSCF concentrations were more than 3.5-fold higher than in wildtype mice because of feedback mechanisms compensating for markedly reduced c-Kit activity. However, W/W V mice rescued by wild-type BM transplantation had much lower levels of sSCF than the W/W V mice (146Ϯ8 versus 315Ϯ10 ng/mL, PϽ0.001; wild-type values are 91Ϯ9 ng/mL). This phenomenon could explain why rescued W/W v mice had only similar rather than more intimal hyperplasia compared with wildtype mice ( Figure 2C ). Plasma sSCF levels in Sl/Sl d mice were substantially lower than in wild-type mice and only increased slightly on day 7 after injury. MMP-9 Ϫ/Ϫ mice exhibited sSCF baseline concentrations that were similar to wild-type mice; however, the levels of sSCF did not change in response to vascular injury, as expected, because MMP-9 facilitates the shedding of mSCF. 23, 24 Plasma G-CSF levels transiently increased 1 day after vascular injury in all mice ( Figure 3B ), but the rate of decline in the vascular injured wild-type mice was slower than in the sham-operated mice.
MMP-9 Facilitates SCF Shedding
SCF levels increased following vascular injury because of upregulated MMP-9 activity within the injured vasculature. At 1 and 7 days after injury, SCF expression was detected at areas that also contained higher levels of MMP-9 ( Figure  4A ). In addition, our data suggested that MMP-9 was activated to cleave mSCF, which was expressed throughout the vessel wall (data not shown). Zymography demonstrated a marked upregulation of pro-MMP-9 and active MMP-9 1 day after injury, with the majority of MMP-9 being in the active form by day 7 (Figure 4B ). Vascular injury in MMP-9 Ϫ/Ϫ mice resulted in modest neointimal formation; however, when the mice were supplemented with sSCF for 2 weeks after vascular injury, a 2.5-fold increase in neointimal formation was observed ( Figure 4C ). Thus, MMP-9 -induced release of SCF appears to be a prerequisite for aberrant vascular remodeling following injury. In the BM, femoral artery wire injury also induced a significant increase in MMP-9 activity. Pharmacological inhibition of MMP activity led to significantly increased mSCF ϩ cell numbers in response to the injury. However, without MMP inhibition, mSCF ϩ cell numbers increased transiently and then significantly decreased at later time points. These findings suggested that MMP-9 was activated inside the BM and cleaved mSCF, contributing in part to the increase in circulating sSCF levels (supplemental Figure V ).
Vascular Injury Promotes Progenitor Cell Mobilization
As of yet, the markers of smooth muscle PCs have not been clearly defined. However, Simper et al reported that circulating smooth muscle PCs appear to originate from CD34 ϩ cells. 29 Thus, CD34 was used as a surrogate for PC mobilization in this study. The increase in sSCF levels following vascular injury in wild-type mice coincided with a significant increase in the number of circulating BM-derived CD34 ϩ PCs ( Figure 3C ). The level of circulating CD34 ϩ cells appeared to increase in 2 waves, rising immediately after vascular injury and again 9 days later. The effect of sSCF on CD34 ϩ cell mobilization was confirmed ( Figure 3D ). However, injection of sSCF (100 ng/kg per day) could only increase the level of circulating CD34 ϩ cells in MMP-9 Ϫ/Ϫ mice and not in Sl/Sl d mice, suggesting a requirement for mSCF in mobilization rather than only a change in serum SCF. Treatment with imatinib mesylate (Gleevec), a c-Kit-kinase inhibitor, inhibited both early and late CD34 ϩ cell mobilization ( Figure 3C) . Similarly, Sl/Sl d mice displayed impaired cell mobilization.
SCF Contributes to the Differentiation of Progenitor Cells After Vascular Injury
To ascertain whether SCF contributed to the homing and differentiation of PCs after vascular injury, we directly tested the influence of SCF on BM PC adhesion (because cell adhesion is required in homing) and smooth muscle differentiation. Negatively selected Lin Ϫ cells, which were enriched with c-Kit ϩ cells, were used in the adhesion experiments. Lin Ϫ cells rather than directly isolated c-Kit ϩ cells were used to avoid blocking the c-Kit receptor by the primary anti-c-Kit antibody used for the positive selection processes. SCF (200 ng/mL) induced a 2.3-fold increase in the adhesion of Lin Ϫ BM cells to fibronectin ( Figure 5A ). This effect was completely blocked by an anti-␣ 5 ␤ 1 integrin antibody. In a second adhesion assay, rat VSMCs were activated by PDGF (10 ng/mL) to upregulate the expression of SCF. Activated VSMCs greatly increased the adhesion of Lin Ϫ BM cells, an interaction that was blocked by administration of anti-SCF antibody ( Figure 5B and 5C ). Furthermore, the coculture of eYFP ϩ Lin -BM cells with activated VSMCs for 11 days showed clusters of cells that expressed both eYFP and ␣SMA ( Figure 5D, top) . Adding anti-SCF antibody to the coculture decreased the number of double-positive cells ( Figure 5D , bottom), suggesting that VSMC activation, marked by SCF expression, is not only required for PC homing but also PC differentiation toward the smooth muscle cell (SMC) lineage.
c-Kit ؉ Cells Give Rise to ␣SMA ؉ Cells
c-Kit ϩ and c-Kit Ϫ BM cells were purified and tested for their potential to differentiate into ␣SMA ϩ cells in low-serum endothelial growth medium-2 (EGM-2). Compared with c-Kitcells a week after plating, c-Kit ϩ cells exhibited increased survival and gave rise to more ␣SMA ϩ cell colonies (approximately 5-fold increase) ( Figure 6A ). Once c-Kit ϩ cells expressed ␣SMA ϩ , they lost both the c-Kit and CD45 phenotypes. This also appeared to be the case in vivo.
Although a significant amount of c-Kit ϩ cells were noted to adhere to the injured vascular wall in the littermate control mice ( Figure 6B and 6C) , once these c-Kit ϩ cells differentiated into ␣SMA ϩ cell, c-Kit expression became very weak or disappeared ( Figure 6D) . These cells underwent a remarkable extent of proliferation to cause intimal hyperplasia ( Figure  6E ). However, in the Sl/Sl d mice, essentially no c-Kit ϩ cells could be detected in the neointima at the early time point after injury ( Figure 6C ).
Blocking c-Kit Signaling Attenuates Neointimal Hyperplasia
Imatinib mesylate is a protein-tyrosine kinase inhibitor, which selectively blocks Abl tyrosine kinase and the c-Kit and PDGF receptor (PDGF-R) tyrosine kinases. 30, 31 Early intervention with imatinib mesylate significantly attenuated neointimal formation, an average of 300% reduction, whereas imatinib mesylate treatment that started at the hyperplasia phase was ineffective ( Figure 7A and 7B) . Because imatinib mesylate also inhibits PDGF-R signaling, which is well known to mediate SMC proliferation, we analyzed the kinetics of PDGF-R␤ expression following injury. Figure 7C demonstrates that PDGF-R␤ was primarily expressed within the adventitia and to a lesser degree by VSMCs and that the expression of PDGF-R␤ by medial SMCs was upregulated beginning 9 days after vascular injury. In contrast, c-Kit ϩ cells appeared within the vessel medial wall by 1 day after vascular injury (supplemental Figure VI) . Imatinib mesylate did not affect the sSCF and G-CSF levels after vascular injury (data not shown). Finally, we hypothesized that if the imatinib mesylate-mediated inhibition of neointimal hyperplasia was acting through the c-Kit pathway, then blocking c-Kit activation using the blocking anti-c-Kit receptor monoclonal antibody ACK2 would generate similar results. In fact, we found a significant attenuating effect by ACK2 on intimal hyperplasia (Figure 7D ).
Discussion
We have defined a new mechanistic pathway of neointimal formation and adverse vascular remodeling, critically dependent on the interaction between SCF/c-Kit receptor signaling and the subsequent mobilization of BM-derived PCs. Our conclusions are based on in vivo studies performed in mutant models of SCF deficiency and c-Kit receptor deficiency, with additional supportive data from BM transplantation and pharmacological antagonism studies with imatinib mesylate and blocking c-Kit antibodies. PC mobilization from the BM and subsequent recruitment to the area of injury occurs shortly after the vascular insult; however, intimal hyperplasia accelerates between 14 to 28 days postinjury, possibly secondary to proliferation of the newly recruited PCs. The mobilization and recruitment of PCs from the BM requires the release of SCF via MMP-9 activation. SCF, PDGF, and G-CSF have all been shown to activate MMP-9. [32] [33] [34] Our data suggest 2 waves of PC mobilization following vascular injury: an early, immediate response and a delayed response ( Figure 3C ). Although the early episode may represent a nonspecific response to injury, only mice that underwent vascular injury maintained elevated sSCF levels and displayed the second phase, which became apparent approximately 9 days after vascular injury, just as the neointima was beginning to develop. Both MMP-9 Ϫ/Ϫ and Sl/Sl d mice did not sustain changes to sSCF levels in response to vascular injury ( Figure 3A and  3B) . The observation that supplementation with sSCF only exerted an effect on MMP-9 Ϫ/Ϫ mice, which have normal mSCF but are unable to release it, suggests that mSCF plays a critical role not only in PC mobilization but also in homing and differentiation. mSCF serves as a source of sSCF after wire injury, which may subsequently promote adhesion of PCs to the exposed matrix on the injured vessel and stimulate PDGF release on platelet activation. mSCF plays a critical role in the homing of PCs to the injured vessel wall and mediates the differentiation of c-Kit ϩ PCs to VSMCs ( Figure  5 ). Either a lack of mSCF or the blockade of the c-Kit/mSCF interaction markedly attenuated PC mobilization, homing, and differentiation. Cell adhesion is only 1 component of PC homing, and we have not investigated directed migration of PCs, which may also play a role in modulating the effects of SCF on PC homing. Although wild-type BM repopulation of W/W v mice restored neointimal hyperplasia following injury, demonstrating the requirement of the SCF/c-Kit pathway and BM cells in our model, the reciprocal experiment could not be performed. Classic BM transplantation experiments performed in the 1960s demonstrated that W/W v hematopoietic stem cells are incompetent to repopulate wild-type mice. Furthermore, wild-type BM cannot repopulate Sl/Sl d mice because of a lack of SCF expressed by the stromal cells within the hematopoietic stem cell niche. 35 Although we have clearly shown that restenosis in our mouse model is dependent on the c-Kit signaling pathway, how do these findings translate to human pathology and clinical practice? For example, the mouse femoral artery injury model represents a severe vascular injury model, which requires the participation of BM-derived progenitors in the repair process, and it has been shown that less severe injury models do not necessarily recruit BM-mobilized cells. 36 Although it is important to not overextrapolate mouse data to human clinical data, there are several lines of evidence suggesting that c-Kit/SCF-induced mobilization of BM progenitors is clinically relevant and that imatinib mesylate therapy should be considered. First, although the extent of vascular injury is considerably less severe in human angioplasty, in this era of extensive vascular stent intervention, a similar stress on the vessel wall, as observed in the mouse model, may exist, attracting BM cells through the SCF/c-Kit pathway as atherosclerotic plaques are being pushed outward. Supporting this hypothesis are findings that BM-derived cells including monocytes are mobilized following coronary stent implantation and the number of circulating cells directly correlated with in-stent neointimal volume. 37 More directly, Figure 6 . c-Kit ϩ cells give rise to ␣SMA ϩ cells. A, c-Kit ϩ cells differentiated into ␣SMA ϩ cells (top). ␣SMA (red), CD45 (green) and nuclei (blue). Bottom, c-Kit Ϫ cells are shown (nϭ6). B, Immunofluorescence triple staining on a femoral artery of eYFP BM cell-reconstituted wild-type mouse 5 days after injury: c-Kit (red), eYFP (green), and nucleus (blue). Arrows and arrowheads indicate c-Kit ϩ cells and internal elastic lamina, respectively. C, Triple staining on femoral arteries from littermate controls and Sl/Sl d mice 7 days after injury: c-Kit (green), ␣SMA (red), and nucleus (blue). D, Immunofluorescence staining on a femoral artery 28 days after injury. E, Immunohistochemical staining of Ki-67 (a marker of cell proliferation) on vessels 3, 14, and 21 days after injury. Figure 7 . Imatinib mesylate treatment attenuates neointimal hyperplasia in mice following vascular injury. A and B, Treatment with imatinib mesylate at an early period (3 days before or up to 7 days after injury) attenuated intimal hyperplasia. Late treatment (after 14 days) had no effect. The intima/media ratio was measured (nϭ6 to 10). C, The expression of the PDGF-R␤ on vascular wall after injury. D, Treatment with ACK2 significantly attenuated intimal hyperplasia (3 days before or up to 10 days after vascular injury) (nϭ6 to 10). *PϽ0.01, compared with control.
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c-Kit ϩ vascular progenitors have been identified within postangioplasty restenosis lesions. 38 Moreover, a recent clinical trial performed on MI patients designed to test the efficacy and safety of mobilization of BM progenitors to improve cardiac function was halted because of the high rate of restenosis. The MAGIC clinical trial performed G-CSFmediated mobilization of BM progenitors on patients with MI who underwent coronary stenting. Although cardiac function improved in these patients, the study ended prematurely because patients receiving G-CSF experienced an unexpectedly high rate of postangioplasty restenosis. 11 As discussed above, G-CSF-induced mobilization acts through MMP-9 to cleave mSCF and activate c-Kit ϩ to proliferation and mobilize into the periphery. Imatinib mesylate prevented adverse vascular remodeling when administered early after vascular injury, at a stage when c-Kit signaling is essential for PC mobilization and recruitment. This finding was mirrored by intervention with ACK2, a neutralizing anti-c-Kit receptor monoclonal antibody, further strengthening our conclusion that the action of imatinib mesylate by blocking the SCF/c-Kit pathway. However, imatinib mesylate may also have a role in blocking postangioplasty restenosis mediated by local vascular SMCs by blocking PDGFR tyrosine kinase activity. PDGF is a wellknown potent mitogenic and migratory factor for vascular SMCs and has been implicated in vascular pathologies. 39 Imatinib mesylate, either alone or in combination with other treatments, has in some cases been demonstrated to reduce the extent of restenosis through its effect on PDGF receptors. 40 -42 Our data suggest that c-Kit signaling is upstream of the PDGF-mediated pathway recruitment of perivascular cells; however, much more work must be done to discover the biochemical and cellular interactions between these 2 tyrosine kinases pathways in neointima formation.
In summary, we demonstrated that the SCF/c-Kit pathway is a novel, important, and logical target for therapeutic intervention to reduce neointimal formation and adverse vascular remodeling by BM-derived PCs. Using mutant models of SCF and c-Kit deficiency in addition to BM rescue and pharmacological antagonism approaches (imatinib mesylate or ACK2), we implicate a fundamental role of SCF/c-Kit signaling as a critical determinant of BM cell contribution to neointimal formation following arterial injury. Although preclinical 4 and clinical evidence suggests that it is efficacious to induce mobilization of c-Kit ϩ cells into the heart to effect cardiac repair following MI, we have shown in this report that it is critical to avoid mobilization of c-Kit ϩ smooth muscle progenitors to sites of vascular injury. 43 These data provide a rationale for testing directed therapies aimed at limiting the BM contribution to vascular injury (by interrupting the SCF/c-Kit pathway) in patients undergoing vascular interventions such as bypass grafting and angioplasty.
